{"url":"https://whatshealthyandwhy.com/devils-claw/joint-pain-and-anti-inflammatory","path":"/devils-claw/joint-pain-and-anti-inflammatory","alternates":{"json":"https://whatshealthyandwhy.com/api/articles/devils-claw/joint-pain-and-anti-inflammatory.json","markdown":"https://whatshealthyandwhy.com/devils-claw/joint-pain-and-anti-inflammatory.md"},"topic":{"slug":"devils-claw","name":"Devil's Claw","url":"https://whatshealthyandwhy.com/devils-claw"},"slug":"joint-pain-and-anti-inflammatory","order":1,"title":"Joint Pain, Back Pain, and Anti-Inflammatory Effects","question":"Does devil's claw relieve joint pain and low back pain?","answer":"Devil's claw likely eases low back and osteoarthritis pain when standardized to harpagoside, but most trials are older and of moderate quality.","description":"How devil's claw (Harpagophytum procumbens) relieves osteoarthritis, back pain, and inflammation through its active harpagoside compounds","confidence":3,"confidenceNote":"A 12-trial systematic review rated evidence strong for one back pain extract and moderate for osteoarthritis; the two individual studies were uncontrolled.","evidenceSummary":{"observationalCount":2,"metaAnalysisCount":2,"totalParticipants":"330+","replicated":true,"newestStudyYear":2008},"category":{"categoryTitle":"What's Good For You","categorySlug":"good-for-you","subcategoryName":"Herbs & Spices","subcategorySlug":"herbs","url":"https://whatshealthyandwhy.com/explore/good-for-you/herbs"},"actions":["Choose a product standardized to harpagoside, not raw herb weight; the best-supported dose was an aqueous extract giving 50 mg harpagoside daily [1].","Take it with food, since it may mildly increase stomach acid and can cause nausea or diarrhea at higher doses.","Judge it over 8–12 weeks, the length of the studies; benefit beyond 12–16 weeks is untested [2][5]."],"cautions":["Check with your doctor if you take warfarin or other blood thinners, or drugs processed by CYP450 enzymes; devil's claw can modestly interact.","Avoid in pregnancy (harpagoside may stimulate uterine contractions) and use caution with peptic ulcer disease or reflux.","Safety data support short-to-medium-term use only; serious liver or kidney harm was not reported in standard-dose trials [3]."],"simpleText":"Devil's claw is a plant native to the Kalahari Desert of southern Africa, prized for centuries by indigenous peoples for treating joint pain, fever, and digestive complaints. Its twisted, claw-shaped seed pods give the plant its name, but the medicine comes from its secondary storage tubers. Those tubers contain harpagoside, a potent anti-inflammatory iridoid glycoside with well-documented effects on pain and stiffness. Clinical trials support its use for osteoarthritis of the hip, knee, and spine, as well as for acute and chronic low back pain — with a safety profile that compares favorably to conventional NSAIDs [1][2][3].","mediumText":"How Devil's Claw Works\n\nDevil's claw (Harpagophytum procumbens) contains three primary active compounds: harpagoside, harpagide, and procumbide. Of these, harpagoside is the most pharmacologically significant and is used as the standard measure of extract potency.\n\nAnti-inflammatory mechanism: Harpagoside inhibits multiple inflammatory pathways simultaneously. It suppresses cyclooxygenase-2 (COX-2) and 5-lipoxygenase (LOX), two key enzymes that produce prostaglandins and leukotrienes — the signaling molecules that drive pain and swelling. It also downregulates NF-κB, a central transcription factor that amplifies inflammatory gene expression, and reduces production of pro-inflammatory cytokines including TNF-alpha and interleukin-1 beta. This multi-pathway action is thought to explain why clinical effects appear across a range of inflammatory conditions.\n\nImportant distinction from NSAIDs: Unlike conventional anti-inflammatories such as ibuprofen or naproxen, devil's claw appears to work without significantly inhibiting COX-1, the prostaglandin enzyme that protects the stomach lining. This may explain why it is generally better tolerated gastrointestinally, though head-to-head comparisons are limited.\n\nOsteoarthritis\n\nThe strongest evidence is for osteoarthritis of load-bearing joints. A 2003 multicentre drug surveillance study of 75 patients with arthrosis of the hip or knee used a standardized aqueous extract (Doloteffin) at 2400 mg daily — equivalent to 50 mg harpagoside — for 12 weeks. Pain scores dropped substantially, with Algofunctional Index scores improving by an average of 25% for hip and 23% for knee. Patient and physician global assessments were positive, and laboratory markers including liver function tests remained stable [2].\n\nA 2004 systematic review of 12 trials found moderate evidence supporting a powder preparation standardized to 60 mg harpagoside for osteoarthritis of the spine, hip, and knee, and strong evidence for an aqueous extract at 50 mg harpagoside daily for acute exacerbations of chronic non-specific low back pain [1].\n\nLow Back Pain\n\nLow back pain is the condition with the most consistent and highest-quality evidence for devil's claw. Several randomized controlled trials have compared standardized devil's claw extracts to placebo and, in some cases, to conventional analgesics. The results consistently show meaningful reductions in pain intensity, improved mobility, and reduced reliance on rescue medication. The systematic review by Gagnier et al. rated the evidence for the 50 mg harpagoside aqueous extract as \"strong\" — a designation not given lightly in herbal medicine literature [1].\n\nWhole-Body Rheumatic Conditions\n\nAn 8-week open observational study of 259 UK patients with general arthritis and rheumatic conditions found statistically significant improvements in pain, stiffness, and physical function, measured using the WOMAC Index and numeric rating scales. Pain improved across all tracked joint sites — hands, wrists, elbows, shoulders, hips, knees, and back. Notably, 60% of patients reduced or discontinued their concomitant pain medications during the study [5].\n\nDosage and Forms\n\n- Standardized aqueous extract: 2400 mg/day (delivering 50 mg harpagoside), the most studied and best-supported dose\n- Standardized powder: 2610 mg/day (delivering 60 mg harpagoside), supported for osteoarthritis\n- Fresh herb tincture or tea: traditionally used but harpagoside content is variable; standardization is important for reliable effects\n\nLook for products standardized to harpagoside content rather than raw herb weight, as potency varies considerably between preparations.\n\nPractical Notes\n\nDevil's claw is generally well-tolerated. The most common side effects are mild gastrointestinal symptoms (nausea, diarrhea, stomach discomfort) at higher doses. Because it may mildly stimulate gastric acid secretion, it is best taken with food and used with caution in peptic ulcer disease or gastroesophageal reflux.\n\nDrug interactions to be aware of: devil's claw can modestly interact with anticoagulants (warfarin), and there are theoretical interactions with medications metabolized by CYP450 enzymes. People on blood thinners should consult a healthcare provider before use.\n\nIt is not recommended during pregnancy, as harpagoside has oxytocic properties (may stimulate uterine contractions) at higher doses.\n\nFor additional anti-inflammatory approaches see our Boswellia page and our Cat's Claw page, both of which target NF-κB and COX pathways similarly.","deepText":"Evidence Review\n\nSystematic Review: Osteoarthritis and Low Back Pain\n\nGagnier, Chrubasik, and Manheimer (2004) published a systematic review in BMC Complementary and Alternative Medicine (PMID 15369596) examining 12 trials of Harpagophytum preparations for musculoskeletal pain. Six trials investigated osteoarthritis, four examined low back pain, and three assessed mixed pain conditions. The authors found three distinct evidence levels depending on preparation and dose:\n\n- Limited evidence for an ethanolic extract containing less than 30 mg harpagoside per day in knee and hip osteoarthritis\n- Moderate evidence for a powder extract standardized to 60 mg harpagoside per day in osteoarthritis of the spine, hip, and knee\n- Strong evidence for an aqueous extract delivering 50 mg harpagoside per day in acute exacerbations of chronic non-specific low back pain\n\nThe review concluded that devil's claw, when properly standardized, shows a meaningful efficacy signal across multiple pain conditions, with the strongest evidence for low back pain. The authors noted that many trials were of moderate methodological quality, but the consistency of findings across independent research groups lends credibility to the overall conclusion.\n\nClinical Study: Hip and Knee Arthrosis\n\nWegener and Lüpke (2003) conducted a prospective, multicenter, uncontrolled 12-week drug surveillance study of 75 patients with diagnosed hip or knee arthrosis, published in Phytotherapy Research (PMID 14669250). All patients received Doloteffin, a standardized aqueous extract of Harpagophytum at 2400 mg/day (50 mg harpagoside). Primary outcomes were the Algofunctional Index score (a composite measure of pain and functional limitation) and patient and physician global assessments.\n\nResults showed a 25% improvement in Algofunctional Index for hip arthrosis and 23% for knee arthrosis. Pain at rest, pain on movement, and morning stiffness all improved significantly. Global assessment was rated as \"good\" or \"very good\" by 60% of patients and 57% of physicians. Liver function tests, blood counts, and other safety parameters remained within normal limits throughout. The uncontrolled design limits causal interpretation, but the magnitude and consistency of improvement across 75 patients is notable.\n\nSafety Systematic Review\n\nVlachojannis, Roufogalis, and Chrubasik (2008) published a systematic review focused specifically on safety in Phytotherapy Research (PMID 18236448). Reviewing available clinical trial data, they found that:\n\n- Adverse events were generally mild and transient, primarily gastrointestinal (nausea, diarrhea, stomach upset)\n- No serious hepatotoxicity or nephrotoxicity was reported in any included trial\n- Liver function tests remained stable in studies that tracked them\n- The authors concluded that devil's claw preparations used in standard doses have an acceptable safety profile for short-to-medium-term use\n\nThis safety review is important context for practitioners and patients: the anti-inflammatory activity of harpagoside does not appear to carry the ulcerogenic and nephrotoxic risks associated with long-term NSAID use, at least at typical therapeutic doses and durations.\n\nReview of Efficacy and Safety for Osteoarthritis\n\nBrien, Lewith, and McGregor (2006) reviewed the clinical evidence for devil's claw specifically in osteoarthritis, in the Journal of Alternative and Complementary Medicine [4]. They found 14 studies: eight observational studies, two comparator trials, and four double-blind, placebo-controlled randomized trials. Many lacked important methodological quality criteria, but the data from the higher-quality studies suggested that devil's claw appeared effective in reducing pain. Safety assessment was limited by small study populations; devil's claw appeared to carry minor risk relative to NSAIDs, but long-term assessment is needed. The authors concluded that the methodological quality of the trials was generally poor, that the evidence could not yet answer definitively whether it works or is safe, and that a definitive high-quality trial is needed.\n\nObservational Study: General Rheumatic Disorders\n\nWarnock et al. (2007) conducted an 8-week single-group open study of 259 patients with arthritis and general rheumatic conditions in the United Kingdom, published in Phytotherapy Research (PMID 17886223). Using the WOMAC Index and numeric pain rating scales, they observed statistically significant reductions in pain across all tracked joint locations, improved stiffness scores, and enhanced physical function. Quality of life, measured by the SF-12, also improved significantly. The striking finding was that 60% of patients reduced or completely stopped concomitant pain medications during the study period. No serious adverse events were reported. While the lack of a control group limits interpretation, the size of the sample and the breadth of outcomes tracked make this one of the larger real-world observations of devil's claw for musculoskeletal conditions.\n\nStrength of Evidence\n\nDevil's claw has one of the more robust evidence bases among herbal anti-inflammatories, particularly for low back pain. The Gagnier et al. systematic review's \"strong evidence\" classification for the aqueous extract at 50 mg harpagoside for acute low back pain is notable — few herbal preparations reach this designation. For osteoarthritis, the evidence is moderate, consistently positive across multiple independent research groups, but limited by small sample sizes and variable trial quality. The safety literature is reassuring, showing no serious liver, kidney, or gastrointestinal toxicity at standard doses and durations. …","deepTruncated":true,"references":[{"id":"1","title":"Harpagophytum procumbens for osteoarthritis and low back pain: a systematic review","authors":"Gagnier JJ, Chrubasik S, Manheimer E","year":2004,"journal":"BMC Complementary and Alternative Medicine","pmid":"15369596","url":"https://pubmed.ncbi.nlm.nih.gov/15369596/"},{"id":"2","title":"Treatment of patients with arthrosis of hip or knee with an aqueous extract of devil's claw (Harpagophytum procumbens DC.)","authors":"Wegener T, Lüpke NP","year":2003,"journal":"Phytotherapy Research","pmid":"14669250","url":"https://pubmed.ncbi.nlm.nih.gov/14669250/"},{"id":"3","title":"Systematic review on the safety of Harpagophytum preparations for osteoarthritic and low back pain","authors":"Vlachojannis J, Roufogalis BD, Chrubasik S","year":2008,"journal":"Phytotherapy Research","pmid":"18236448","url":"https://pubmed.ncbi.nlm.nih.gov/18236448/"},{"id":"4","title":"Devil's Claw (Harpagophytum procumbens) as a treatment for osteoarthritis: a review of efficacy and safety","authors":"Brien S, Lewith G, McGregor G","year":2006,"journal":"Journal of Alternative and Complementary Medicine","pmid":"17212570","url":"https://pubmed.ncbi.nlm.nih.gov/17212570/"},{"id":"5","title":"Effectiveness and safety of Devil's Claw tablets in patients with general rheumatic disorders","authors":"Warnock M, McBean D, Suter A, Tan J, Whittaker P","year":2007,"journal":"Phytotherapy Research","pmid":"17886223","url":"https://pubmed.ncbi.nlm.nih.gov/17886223/"}],"wordCount":1556,"source":{"path":"src/content/topics/devils-claw/joint-pain-and-anti-inflammatory.md"},"citeAs":"“Does devil's claw relieve joint pain and low back pain?.” What's Healthy and Why. https://whatshealthyandwhy.com/devils-claw/joint-pain-and-anti-inflammatory","notice":"General information backed by peer-reviewed research, not medical advice."}